Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12367678 | 0.86 | EPHX1 (0.31) | EPHX1 | |
| SCHEMBL441379 | 0.74 | CA1 (0.31) | EPHX1 | |
| SCHEMBL12883265 | 0.64 | CYP19A1 (0.43) | MAPK1CYP3A4KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL19513338 | 0.64 | ADCY2 (0.35) | MAPK1CYP3A4TSHRGMNNBLM | |
| SCHEMBL10834495 | 0.63 | NPC1 (0.32) | MAPK1 | |
| SCHEMBL11598728 | 0.63 | MAPT (0.36) | — | |
| SCHEMBL9418510 | 0.62 | MEN1 (0.35) | MAPK1CYP3A4KMT2ACYP2C19 | |
| SCHEMBL10835098 | 0.62 | POLB (0.34) | MAPK1CYP3A4KMT2ACYP2C19 | |
| SCHEMBL2172992 | 0.62 | CHRM2 (0.39) | CYP3A4CYP2D6HIF1ACHRM2KMT2A | |
| SCHEMBL11941046 | 0.62 | CYP2D6 (0.41) | TSHRCYP2D6CHRM2KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481558-B2 | Compounds to inhibit or augment an inflammatory response | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2386565-A2 | Compounds and methods to inhibit or augment an inflammatory response | Cambridge Enterprise Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-7989466-B2 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-7989466-B2 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| EP-1012187-B1 | CHEMOKINE PEPTIDES, VARIANTS, DERIVATIVES AND ANALOGS. THEIR USE IN METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE ENTPR LTD (GB) | 2009-08-26 | — | — | EP | disclosed |
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. | 2008-02-21 | — | — | US | disclosed |
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. | 2008-02-21 | — | — | US | disclosed |
| US-7238711-B1 | Compounds and methods to inhibit or augment an inflammatory response | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2007-07-03 | — | — | US | disclosed |
| US-7238711-B1 | Compounds and methods to inhibit or augment an inflammatory response | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2007-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CCL2, CCL11, CCL5 | MAPK1 1583/4885CYP3A4 4136/4885TSHR 1767/4885 |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CCL2, CCL5, CCL11 | MAPK1 1589/4885CYP3A4 4397/4885TSHR 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.